In trial SAKK 67/20 the safety, tolerability and effect of different doses of docetaxel micellar are being investigated in patients with metastatic, castration-resistant prostate cancer (mCRPC).

A maximum of 18 patients with mCRPC who have not already undergone chemotherapy can take part in the trial.

For more information on where and how this trial is conducted, consult the trial website.